Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

Evaporative Dry Eye Disease Clinical Trial

Official title:
A Multi-Center, Single Arm, Post-Market Clinical Follow-up Study to Evaluate the Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye

Status Completed

Clinical Trial Summary

This PMCF study is carried out following successful CE marking of NovaTears® + Omega-3 and is intended to generate systematic clinical data on the safety and performance of the device when used in accordance with the intended purpose.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04521465
Study type	Observational
Source	Novaliq GmbH
Contact
Status	Completed
Phase
Start date	November 9, 2020
Completion date	February 17, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT03833882` - Evaluation of MAF-1217 in Patients With DED	N/A
Completed	`NCT03843983` - Effect of Thermal Pulsation System (Lipiflow) Treatment for Ocular Surface Disease Due to Meibomian Gland Dysfunction	N/A
Completed	`NCT03956225` - Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study	N/A
Completed	`NCT02004067` - Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Phase 4
Completed	`NCT06242860` - Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease	N/A